Skip to main content

Robert J Chilton

Robert J. Chilton, DO FACC FAHA, is Professor of Medicine, Director of the Cardiac Catheterization Laboratory at the University of Texas Health Science Center at San Antonio and director clinical proteomics UTHSCSA/NHLBI. A fellow of the American College of Cardiology, American College of Physicians, American College of Osteopathic Internists, and American Heart Association, Dr. Chilton has chaired the Electrophysiology Board Examination for the American Osteopathic Association in addition to Interventional Board of Examiners.

Over the past 20 years, Dr. Chilton has authored numerous articles, book chapters, abstracts, and presentations on cardiology. He has developed educational materials and has lectured widely, garnering several awards for his academic contributions, including 1994, 2014 Outstanding Teacher from the University of Texas Health Science Center at San Antonio, researcher of the year ACOI. He is associate editor for Catheterization and Cardiovascular Interventions, Clinical Diabetes and on the editorial board of Diabetes Care, American Journal of Cardiology and others.  In addition, he is a cardiology consultant to NASA. His research areas include cardiovascular disease, diabetes, vascular biology, proteomics and translational biology.

Dr. Chilton received his residency at the University of Oklahoma Health Science Center, Oklahoma City, Oklahoma; and a cardiology fellowship at the Wilford Hall United States Air Force Medical Center, San Antonio, Texas. Dr. Chilton is board certified in internal medicine, cardiovascular disease, interventional cardiology and electrophysiology.

print
PRINT

Latest contributions from Robert J Chilton

Editorial Board member Jay Shubrook and Advisory Board member Robert Chilton get together once more to discuss best practice tips for identifying and treating hypertension in patients with pre-existing diabetes (12:17).



Learning points include:

  • Strategies to avoid common pitfalls when performing blood pressure measurements.
  • The importance of the blood pressure measurements in determining the risk of cardiovascular events.
  • The benefits of dual-action and preload-targeted therapies in hypertensive patients.
  • Why potassium levels are an important factor to consider before initiating treatment.

« Video 2: Why aren't we reaching blood pressure goals, despite the raised target?



Video 4: Individualization of diabetes treatment: Considerations for frail, elderly patients with heart failure »

In the wake of the revised blood pressure targets, recommended by the American Diabetes Association's 2017 Position Statement and 2018 Standards of Care, Editorial Board member Jay Shubrook and Advisory Board member Robert Chilton discuss clinical approaches to get hypertensive diabetes patients to target more consistently (12:29).


Learning points include:

  • The atherogenic risk posed by diabetes and why blood pressure measurements from the arm-alone may not be sufficient to evaluate the threat in all patients.
  • The benefits and drawbacks of the medication classes indicated for hypertension treatment, such as:
    • Diuretics
    • β-blockers
    • Calcium channel blockers
  • The impact and rationale for targeting blood pressures lower than those indicated in the ADA position statement. 

« Video 2: What are the current recommendations for managing high blood pressure in diabetes patients?



Video 3: When to intervene in patients with diabetes and high blood pressure? »